Two-faced Fcab prevents polymerization with VEGF and reveals thermodynamics and the 2.15 Å crystal structure of the complex

mAbs

Volumn 9, Issue 7, 2017, Pages 1088-1104

  Lobner, Elisabeth ^a   Humm, Anne Sophie ^a,b   Mlynek, Georg ^b   Kubinger, Konstantin ^a   Kitzmüller, Michael ^a   Traxlmayr, Michael W ^a   Djinović Carugo, Kristina ^b,c   Obinger, Christian ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Fcab; heterodimeric Fcab; IgG1 Fc; VEGF; X ray crystallography

Indexed keywords

FUSION PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; PROTEIN BINDING; VASCULOTROPIN A;

CHEMISTRY; HUMAN; IMMUNOLOGY; MOLECULAR DYNAMICS; POLYMERIZATION; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MOLECULAR DYNAMICS SIMULATION; POLYMERIZATION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; THERMODYNAMICS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85029448570     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2017.1364825     Document Type: Article

References (60)

1. Jafari R, Zolbanin NM, Rafatpanah H, Majidi J, Kazemi T. Fc-fusion proteins in therapy: an updated view. Curr Med Chem. 2017;24:1228-37. doi:10.2174/0929867324666170113112759. PMID:28088904
2. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 2009;100:1566-72. doi:10.1111/j.1349-7006.2009.01222.x. PMID:19538497
3. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs. 2011;3:415-6. doi:10.4161/mabs.3.5.17334. PMID:21785279
4. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, Lencer WI, Pierce GF, Blumberg RS. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. 2015;35:235-54. doi:10.3109/07388551.2013.834293. PMID:24156398
5. Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci U S A. 1969;63:78-85. doi:10.1073/pnas.63.1.78. PMID:5257969
6. Halaby DM, Poupon A, Mornon J. The immunoglobulin fold family: sequence analysis and 3D structure comparisons. Protein Eng. 1999;12:563-71. doi:10.1093/protein/12.7.563. PMID:10436082
7. Lobner E, Traxlmayr MW, Obinger C, Hasenhindl C. Engineered IgG1-Fc-one fragment to bind them all. Immunol Rev. 2016;270:113-31. doi:10.1111/imr.12385. PMID:26864108
8. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschlager M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel. 2010;23:289-97. doi:10.1093/protein/gzq005. PMID:20150180
9. Jez J, Antes B, Castilho A, Kainer M, Wiederkum S, Grass J, Rüker F, Woisetschläger M, Steinkellner H. Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments. J Biol Chem. 2012;287:24313-9. doi:10.1074/jbc.M112.360701. PMID:22589538
10. Woisetschlager M, Antes B, Borrowdale R, Wiederkum S, Kainer M, Steinkellner H, Wozniak-Knopp G, Moulder K, Rüker F, Mudde GC. In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites. Biotechnol J. 2014;9:844-51. doi:10.1002/biot.201300387. PMID:24806546
11. Traxlmayr MW, Lobner E, Antes B, Kainer M, Wiederkum S, Hasenhindl C, Stadlmayr G, Rüker F, Woisetschläger M, Moulder K, et al. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display. Protein Eng Des Sel. 2013;26:255-65. doi:10.1093/protein/gzs102. PMID:23267121
12. Lobner E, Humm AS, Goritzer K, Mlynek G, Puchinger MG, Hasenhindl C, Rüker F, Traxlmayr MW, Djinović-Carugo K, Obinger C. Fcab-HER2 interaction: a menage a trois. Lessons from X-Ray and solution studies. Structure. 2017;25:878–89 e5. doi:10.1016/j.str.2017.04.014
13. Leung KM, Batey S, Rowlands R, Isaac SJ, Jones P, Drewett V, Carvalho J, Gaspar M, Weller S, Medcalf M, et al. A HER2-specific modified Fc Fragment (Fcab) induces antitumor effects through degradation of HER2 and apoptosis. Mol Ther. 2015;23:1722-33. doi:10.1038/mt.2015.127. PMID:26234505
14. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997;15:553-7. doi:10.1038/nbt0697-553. PMID:9181578
15. Muller YA, Heiring C, Misselwitz R, Welfle K, Welfle H. The cystine knot promotes folding and not thermodynamic stability in vascular endothelial growth factor. J Biol Chem. 2002;277:43410-6. doi:10.1074/jbc.M206438200. PMID:12207021
16. Ahmed AA, Giddens J, Pincetic A, Lomino JV, Ravetch JV, Wang LX, Bjorkman PJ. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol. 2014;426:3166-79. doi:10.1016/j.jmb.2014.07.006. PMID:25036289
17. Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol. 2012;7:1596-602. doi:10.1021/cb300130k. PMID:22747430
18. Teplyakov A, Zhao Y, Malia TJ, Obmolova G, Gilliland GL. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface. Mol Immunol. 2013;56:131-9. doi:10.1016/j.molimm.2013.03.018. PMID:23628091
19. Fersht A. Structure and mechanism in protein science: a guide to enzyme catalysis and protein folding. W. H. Freeman; 1999; 10-12.
20. Barlow DJ, Thornton JM. Helix geometry in proteins. J Mol Biol. 1988;201:601-19. doi:10.1016/0022-2836(88)90641-9. PMID:3418712
21. Hardy JA, Nelson HC. Proline in alpha-helical kink is required for folding kinetics but not for kinked structure, function, or stability of heat shock transcription factor. Protein Sci. 2000;9:2128-41. doi:10.1110/ps.9.11.2128. PMID:11305238
22. Fu H, Grimsley GR, Razvi A, Scholtz JM, Pace CN. Increasing protein stability by improving beta-turns. Proteins. 2009;77:491-8. doi:10.1002/prot.22509. PMID:19626709
23. Spreter Von Kreudenstein T, Escobar-Carbrera E, Lario PI, D'Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH, et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs. 2013;5:646-54. doi:10.4161/mabs.25632. PMID:23924797
24. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A. Protein Identification and Analysis Tools on the ExPASy Server. In: John M. Walker, editor. The Proteomics Protocols Handbook. Humana Press; 2005. p. 571-607.
25. Harris RJ. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A. 1995;705:129-34. doi:10.1016/0021-9673(94)01255-D. PMID:7620566
26. van den Bremer ET, Beurskens FJ, Voorhorst M, Engelberts PJ, de Jong RN, van der Boom BG, Cook EM, Lindorfer MA, Taylor RP, van Berkel PH, et al. Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. MAbs. 2015;7:672-80. doi:10.1080/19420862.2015.1046665. PMID:26037225
27. Plomp R, Dekkers G, Rombouts Y, Visser R, Koeleman CA, Kammeijer GS, Jansen BC, Rispens T, Hensbergen PJ, Vidarsson G, et al. Hinge-region o-glycosylation of human immunoglobulin G3 (IgG3). Mol Cell Proteomics. 2015;14:1373-84. doi:10.1074/mcp.M114.047381. PMID:25759508
28. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A. 1997;94:7192-7. doi:10.1073/pnas.94.14.7192. PMID:9207067
29. Piovesan D, Minervini G, Tosatto SC. The RING 2.0 web server for high quality residue interaction networks. Nucleic Acids Res 2016;44:W367-74. doi:10.1093/nar/gkw315. PMID:27198219
30. Jones TD, Carter PJ, Pluckthun A, Vasquez M, Holgate RG, Hotzel I, Popplewell AG, Parren PW, Enzelberger M, Rademaker HJ, et al. The INNs and outs of antibody nonproprietary names. MAbs. 2016;8:1-9. doi:10.1080/19420862.2015.1114320. PMID:26716992
31. Traxlmayr MW, Lobner E, Hasenhindl C, Stadlmayr G, Oostenbrink C, Ruker F, Obinger C. Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution. Biotechnol J. 2014;9:1013-22. doi:10.1002/biot.201300483. PMID:24964247
32. Hasenhindl C, Traxlmayr MW, Wozniak-Knopp G, Jones PC, Stadlmayr G, Ruker F, Obinger C. Stability assessment on a library scale: a rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc. Protein Eng Des Sel. 2013;26:675-82. doi:10.1093/protein/gzt041. PMID:24006374
33. Shusta EV, Holler PD, Kieke MC, Kranz DM, Wittrup KD. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat Biotechnol. 2000;18:754-9. doi:10.1038/77325. PMID:10888844
34. Traxlmayr MW, Obinger C. Directed evolution of proteins for increased stability and expression using yeast display. Arch Biochem Biophys. 2012;526:174-80. doi:10.1016/j.abb.2012.04.022. PMID:22575387
35. Garbett NC, Chaires JB. Thermodynamic studies for drug design and screening. Expert Opin Drug Discov. 2012;7:299-314. doi:10.1517/17460441.2012.666235. PMID:22458502
36. Chodera JD, Mobley DL. Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design. Annu Rev Biophys. 2013;42:121-42. doi:10.1146/annurev-biophys-083012-130318. PMID:23654303
37. Markovic-Mueller S, Stuttfeld E, Asthana M, Weinert T, Bliven S, Goldie KN, Kisko K, Capitani G, Ballmer-Hofer K. Structure of the Full-length VEGFR-1 extracellular domain in complex with VEGF-A. Structure. 2017;25:341-52. doi:10.1016/j.str.2016.12.012. PMID:28111021
38. Brozzo MS, Bjelic S, Kisko K, Schleier T, Leppanen VM, Alitalo K, Winkler FK, Ballmer-Hofer K. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. Blood. 2012;119:1781-8. doi:10.1182/blood-2011-11-390922. PMID:22207738
39. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure. 1998;6:1153-67. doi:10.1016/S0969-2126(98)00116-6. PMID:9753694
40. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293:865-81. doi:10.1006/jmbi.1999.3192. PMID:10543973
41. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer. 2008;8:880-7. doi:10.1038/nrc2505. PMID:18923433
42. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002;30:E9. doi:10.1093/nar/30.2.e9. PMID:11788735
43. Traxlmayr MW, Faissner M, Stadlmayr G, Hasenhindl C, Antes B, Ruker F, Obinger C. Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast. Biochim Biophys Acta Prot Proteomics. 2012;1824:542-9. doi:10.1016/j.bbapap.2012.01.006
44. Heiring C, Muller YA. Folding screening assayed by proteolysis: application to various cystine deletion mutants of vascular endothelial growth factor. Protein Eng. 2001;14:183-8. doi:10.1093/protein/14.3.183. PMID:11342715
45. Christinger HW, Muller YA, Berleau LT, Keyt BA, Cunningham BC, Ferrara N, de Vos AM. Crystallization of the receptor binding domain of vascular endothelial growth factor. Proteins. 1996;26:353-7. doi:10.1002/(SICI)1097-0134(199611)26:3%3c353::AID-PROT9%3e3.0.CO;2-E. PMID:8953654
46. Harris LJ, Skaletsky E, McPherson A. Crystallization of intact monoclonal antibodies. Proteins. 1995;23:285-9. doi:10.1002/prot.340230218. PMID:8592710
47. Kabsch W. Xds. Acta Crystallogr D Biol Crystallogr. 2010;66:125-32. doi:10.1107/S0907444909047337. PMID:20124692
48. Karplus PA, Diederichs K. Linking crystallographic model and data quality. Science. 2012;336:1030-3. doi:10.1126/science.1218231. PMID:22628654
49. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658-74. doi:10.1107/S0021889807021206. PMID:19461840
50. Long F, Vagin AA, Young P, Murshudov GN. BALBES: a molecular-replacement pipeline. Acta Crystallogr D Biol Crystallogr. 2008;64:125-32. doi:10.1107/S0907444907050172. PMID:18094476
51. Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, Moriarty NW, Zwart PH, Hung LW, Read RJ, Adams PD. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr D Biol Crystallogr. 2008;64:61-9. doi:10.1107/S090744490705024X. PMID:18094468
52. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66:486-501. doi:10.1107/S0907444910007493. PMID:20383002
53. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213-21. doi:10.1107/S0907444909052925. PMID:20124702
54. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997;53:240-55. doi:10.1107/S0907444996012255. PMID:15299926
55. DiMaio F, Echols N, Headd JJ, Terwilliger TC, Adams PD, Baker D. Improved low-resolution crystallographic refinement with Phenix and Rosetta. Nat Methods. 2013;10:1102-4. doi:10.1038/nmeth.2648. PMID:24076763
56. Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66:12-21. doi:10.1107/S0907444909042073. PMID:20057044
57. Joosten RP, Joosten K, Murshudov GN, Perrakis A. PDB_REDO: constructive validation, more than just looking for errors. Acta Crystallogr D Biol Crystallogr. 2012;68:484-96. doi:10.1107/S0907444911054515. PMID:22505269
58. Joosten RP, Long F, Murshudov GN, Perrakis A. The PDB_REDO server for macromolecular structure model optimization. IUCrJ. 2014;1:213-20. doi:10.1107/S2052252514009324. PMID:25075342
59. Lutteke T, von der Lieth CW. pdb-care (PDB carbohydrate residue check): a program to support annotation of complex carbohydrate structures in PDB files. BMC Bioinformatics. 2004;5:69. doi:10.1186/1471-2105-5-69. PMID:15180909
60. Agirre J, Iglesias-Fernandez J, Rovira C, Davies GJ, Wilson KS, Cowtan KD. Privateer: software for the conformational validation of carbohydrate structures. Nat Struct Mol Biol. 2015;22:833-4. doi:10.1038/nsmb.3115. PMID:26581513